The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
DREAMM-8: Belantamab mafodotin in lenalidomide-exposed patients with RRMM
|
Analysis of the phase III DREAMM-8 trial (NCT04484623) of belantamab mafodotin, pomalidomide, and dexamethasone (BPd) compared with pomalidomide, bortezomib, and dexamethasone (PVd), in lenalidomide-exposed patients with relapsed/refractory multiple myeloma (RRMM) by Dimopoulos et al.1 has been published in The New England Journal of Medicine this week. The primary end point was progression-free survival (PFS), and disease response and safety were also assessed.
|
| Key learnings: |
|
The DREAMM-8 trial met its primary endpoint; BPd significantly improved PFS (12-month PFS of 71% vs 51% for PVd) and offers deeper, more durable responses compared with PVd in patients with RRMM who have been exposed to lenalidomide. |
|
The high incidence of ocular events with BPd (89%) requires careful management and dose adjustments but does not negate the substantial benefits in disease control. |
|
These findings suggest BPd could be a valuable therapeutic option for managing RRMM, particularly in lenalidomide-refractory cases. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
